Synbio International, Inc. (OTC: SYIN) has officially commenced revenue-generating operations with the launch of its Healing Force™ nutraceutical division and first consumer product, Healing Force™ Anxiety Relief. The announcement, made on August 11, 2026, marks the company's transition from a development-stage entity to an operating business, according to a press release.
The move is part of Synbio's dual-track strategy: combining near-term revenue from wellness products with the long-term potential of its AI-driven facial analysis technology for mental health screening. The company's CEO, Claudio Solitario, emphasized that this is more than a product launch; it is the start of a strategy to create sustainable shareholder value through multiple revenue streams.
The global nutraceuticals market is experiencing significant growth, projected to expand from approximately US$684 billion today to over US$1.1 trillion by 2033, driven by consumer demand for preventative healthcare and natural wellness products. Synbio aims to capitalize on this trend by offering non-pharmaceutical solutions for stress and anxiety, which can be brought to market more rapidly than traditional pharmaceuticals.
The Healing Force™ product line is being developed under the guidance of Dr. David Anderson, M.D., who has extensive experience in nutraceutical research and scientific validation. Dr. Anderson noted that consumers are increasingly seeking evidence-based wellness solutions, and the company's goal is to develop products grounded in scientific principles while addressing the demand for natural approaches to stress management.
Initially, Synbio will market and distribute Healing Force™ products through direct-to-consumer online channels. This capital-efficient strategy allows the company to scale rapidly while preserving financial flexibility for future product introductions. Additional wellness formulations are currently under evaluation for commercialization.
Beyond the nutraceutical division, Synbio continues to advance its healthcare technology initiatives, including the validation of the FacialDx Inc. facial analysis platform for mental health. The company believes this balanced approach provides opportunities for both immediate revenue and long-term value creation.
For more information, visit the company's website at www.synbiointl.com. The original press release is available on NewMediaWire.
This launch represents a significant milestone for Synbio International, as it begins executing its revenue generation strategy and establishes a foundation for future growth in the wellness and healthcare sectors.
